Tegoprazan (50 mg) has been lunched under the brand name PCAB
Dr Reddy’s Laboratories announced the launch of the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in India. Dr Reddy’s launched Tegoprazan (50 mg) under the brand name PCAB.
Tegoprazan is a next-generation potassium-competitive acid blocker. It is indicated for the treatment of
acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive
Gastroesophageal Reflux Disease (NERD) and gastric ulcer. Tegoprazan induces fast onset of action
and can control gastric pH for a prolonged period, potentially offering significant clinical benefit in APD
management.
Tegoprazan is already approved in 21 countries, including South Korea and China. It is currently under registration in several countries and has successfully completed Phase-III trial in the US.
MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy’s, said, “We are happy to launch Tegoprazan (PCAB) in India, reinforcing our commitment to innovation in gastrointestinal diseases treatment – a key focus area for us. Dr Reddy’s has built a strong and trusted presence in the space, backed by a diverse portfolio of well-established brands such as Omez, Razo, and Vono. Our partnership with HK inno.N Corporation for Tegoprazan brings together complementary strengths to enhance patient access to an innovative molecule that addresses critical gaps in acid peptic disease management and improves outcomes.”
Dal-Won Kwak, Chief Executive Officer, HK inno.N Corporation, said, “Through our partnership with Dr Reddy’s, we are honoured to introduce Tegoprazan in the Indian market, recognised as one of
the world’s most significant pharmaceutical markets. Just as the product launches under the brand
name PCAB, we hope that Tegoprazan will establish itself as a leading innovative therapy within the
potassium-competitive acid blockers class in India. We are confident that Tegoprazan will provide a
valuable new treatment option for patients in India and contribute meaningfully to the improvement of
gastrointestinal care.”
